West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xi'an Janssen Pharmaceutical Ltd, Beijing, Chaoyang District, China.
Ann Med. 2024 Dec;56(1):2386635. doi: 10.1080/07853890.2024.2386635. Epub 2024 Aug 12.
This scoping review and meta-analysis aimed to map the evidence regarding prognostic factors in Chinese patients with immunoglobulin light chain (AL) amyloidosis and to identify current research gaps.
We searched EMBASE, PubMed, and CNKI databases from their inception to 15 September 2021. All studies investigated the association between any prognostic factor and target outcomes, including overall survival (OS), progression-free survival (PFS), and end-stage renal disease (ESRD) in Chinese patients with AL amyloidosis.
This scoping review included 52 studies, of which 44 with 6,432 patients contributed to the multivariate prognostic analysis. Multivariate analysis identified a total of 106 factors that correlated with OS, 16 factors with PFS, and 18 factors with ESRD. Five prognostic factors were significantly associated with PFS, and 11 prognostic factors were significantly associated with ESRD. Meta-analysis was only available for prognostic factors without heterogeneous cutoff values, for which hazard ratios (HRs) and their 95% confidence intervals (CIs) were reported. Meta-analysis showed that bone marrow plasma cells (BMCs) (HR: 1.96, 95% CI: 1.21-3.19, < 0.05) and interventricular septal thickness (IVST) (HR: 1.23, 95% CI: 1.10-1.38, < 0.05) were independently associated with OS.
The significant prognostic factors associated with OS, PFS, and ESRD in Chinese patients with AL amyloidosis were related to plasma cell tumor load, biological characteristics, cardiac involvement, renal involvement, population characteristics, and treatment. Further studies should explore additional prognostic factors in patients with AL amyloidosis to develop prognostic models.
本范围综述和荟萃分析旨在绘制中国免疫球蛋白轻链(AL)淀粉样变性患者的预后因素证据图谱,并确定当前的研究空白。
我们从建库起至 2021 年 9 月 15 日检索了 EMBASE、PubMed 和中国知网(CNKI)数据库。所有研究均调查了任何预后因素与目标结局(包括中国 AL 淀粉样变性患者的总生存(OS)、无进展生存(PFS)和终末期肾病(ESRD))之间的关联。
本范围综述纳入了 52 项研究,其中 44 项研究(6432 例患者)纳入了多变量预后分析。多变量分析确定了与 OS 相关的总计 106 个因素、与 PFS 相关的 16 个因素和与 ESRD 相关的 18 个因素。5 个预后因素与 PFS 显著相关,11 个预后因素与 ESRD 显著相关。仅对无异质性截断值的预后因素进行了荟萃分析,报告了风险比(HR)及其 95%置信区间(CI)。荟萃分析显示骨髓浆细胞(BMC)(HR:1.96,95%CI:1.21-3.19, <0.05)和室间隔厚度(IVST)(HR:1.23,95%CI:1.10-1.38, <0.05)与 OS 独立相关。
与中国 AL 淀粉样变性患者 OS、PFS 和 ESRD 相关的显著预后因素与浆细胞瘤负荷、生物学特征、心脏受累、肾脏受累、人群特征和治疗有关。应进一步研究以探索 AL 淀粉样变性患者的其他预后因素,从而建立预后模型。